Mylan launches 2 new generics

CANONSBURG — Mylan N.V. on Friday announced the U.S. launch of two generic drugs.
The company, which is based in Netherlands with its administrative headquarters in Southpointe, said it released its rasagiline tablets, in 0.5-mg and 1-mg, generic versions of of Teva’s Azilect tablets, which are indicated in the treatment of Parkinson’s disease.
The medicine had U.S. sales of approximately $343 million for the 12 months ending March 31, according to QuintilesIMS Health.
Separately, Mylan announced the U.S. release of announced the U.S. launch of zoledronic acid injection in 5 mg/100 mL single dose vial, a generic version of Novartis’ Reclast injection.
The medicine, which is indicated for the treatment of Paget’s disease of bone in men and women, had U.S. sales of approximately $22.1 million for the 12 months ending March 31, according to QuintilesIMS Health.